Atlas Trials

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Clinical trial NCT06864169 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06864169
Sponsor
Merck Sharp & Dohme LLC
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Gastrointestinal Cancer
Start date
2025-04-01
Primary completion
2026-08-18
Enrollment
160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.